Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089067123> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3089067123 endingPage "S331" @default.
- W3089067123 startingPage "S331" @default.
- W3089067123 abstract "Pyrotinib is a new oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor that targets human epidermal growth factor receptor 1 (HER1), HER2, and HER4. Previous studies have confirmed that progression-free survival (PFS) is safe and well-tolerated in advanced breast cancer. However, the efficacy of pyrotinib plus trastuzumab-based dual HER2 blockade in neoadjuvant therapy for early breast cancer is unknown. The present study aimed to explore the efficacy of pyrotinib in neoadjuvant therapy for early breast cancer. This single-group, multicenter, open-label, investigator-initiated phase II study recruited eligible patients, aged 18–70 years with invasive carcinoma, cT2-3N0-3M0 stage, HER2-positive breast cancer. The patients received 320 mg pyrotinib orally once per day for 21 days plus standard chemotherapy (pyrotinib+TCH) with six 21-day cycles of docetaxel (75 mg/m2) plus carboplatin (6 mg/mL/min) and trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance dose). The primary endpoint was to calculate the number of patients who achieved a pathological complete response (pCR, ypT0/is, ypN0). Simon,s two-stage design with a two-sided α error of 5% and a power of 80% was applied for statistical evaluation; the expected pCR rate was 56%. A total of 75 samples was required for the study with a drop rate of 10%; of these, 31 evaluable patients were to be treated in the first stage, and at least 12 patients with pCR were required to continue to the second stage (NCT03735966). The results of the first 31 patients were reported. The pCR of 16 (51.6%) patients, who reached the threshold for the design, was noted. The study is ongoing. The most frequent grade 3 to 4 adverse events were diarrhea (58.1%), anemia (45.2%), and vomiting (16.1%). However, no treatment-related deaths were recorded. The current trial suggests that pyrotinib plus trastuzumab-based standard chemotherapy has promising efficacy and manageable toxicity in patients with HER2-positive early breast cancer in a neoadjuvant setting, and phase III trials are warranted." @default.
- W3089067123 created "2020-10-01" @default.
- W3089067123 creator A5021222857 @default.
- W3089067123 creator A5025719568 @default.
- W3089067123 creator A5030011354 @default.
- W3089067123 creator A5047435118 @default.
- W3089067123 creator A5051842576 @default.
- W3089067123 creator A5053130399 @default.
- W3089067123 creator A5060104751 @default.
- W3089067123 creator A5082570613 @default.
- W3089067123 creator A5088953775 @default.
- W3089067123 date "2020-09-01" @default.
- W3089067123 modified "2023-09-27" @default.
- W3089067123 title "224P Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: A single-group, multicenter, phase II study" @default.
- W3089067123 doi "https://doi.org/10.1016/j.annonc.2020.08.345" @default.
- W3089067123 hasPublicationYear "2020" @default.
- W3089067123 type Work @default.
- W3089067123 sameAs 3089067123 @default.
- W3089067123 citedByCount "2" @default.
- W3089067123 countsByYear W30890671232022 @default.
- W3089067123 crossrefType "journal-article" @default.
- W3089067123 hasAuthorship W3089067123A5021222857 @default.
- W3089067123 hasAuthorship W3089067123A5025719568 @default.
- W3089067123 hasAuthorship W3089067123A5030011354 @default.
- W3089067123 hasAuthorship W3089067123A5047435118 @default.
- W3089067123 hasAuthorship W3089067123A5051842576 @default.
- W3089067123 hasAuthorship W3089067123A5053130399 @default.
- W3089067123 hasAuthorship W3089067123A5060104751 @default.
- W3089067123 hasAuthorship W3089067123A5082570613 @default.
- W3089067123 hasAuthorship W3089067123A5088953775 @default.
- W3089067123 hasBestOaLocation W30890671231 @default.
- W3089067123 hasConcept C121608353 @default.
- W3089067123 hasConcept C126322002 @default.
- W3089067123 hasConcept C143998085 @default.
- W3089067123 hasConcept C203092338 @default.
- W3089067123 hasConcept C2776694085 @default.
- W3089067123 hasConcept C2778239845 @default.
- W3089067123 hasConcept C2778292576 @default.
- W3089067123 hasConcept C2779786085 @default.
- W3089067123 hasConcept C2781190966 @default.
- W3089067123 hasConcept C2781451048 @default.
- W3089067123 hasConcept C530470458 @default.
- W3089067123 hasConcept C535046627 @default.
- W3089067123 hasConcept C71924100 @default.
- W3089067123 hasConceptScore W3089067123C121608353 @default.
- W3089067123 hasConceptScore W3089067123C126322002 @default.
- W3089067123 hasConceptScore W3089067123C143998085 @default.
- W3089067123 hasConceptScore W3089067123C203092338 @default.
- W3089067123 hasConceptScore W3089067123C2776694085 @default.
- W3089067123 hasConceptScore W3089067123C2778239845 @default.
- W3089067123 hasConceptScore W3089067123C2778292576 @default.
- W3089067123 hasConceptScore W3089067123C2779786085 @default.
- W3089067123 hasConceptScore W3089067123C2781190966 @default.
- W3089067123 hasConceptScore W3089067123C2781451048 @default.
- W3089067123 hasConceptScore W3089067123C530470458 @default.
- W3089067123 hasConceptScore W3089067123C535046627 @default.
- W3089067123 hasConceptScore W3089067123C71924100 @default.
- W3089067123 hasLocation W30890671231 @default.
- W3089067123 hasOpenAccess W3089067123 @default.
- W3089067123 hasPrimaryLocation W30890671231 @default.
- W3089067123 hasRelatedWork W1967391695 @default.
- W3089067123 hasRelatedWork W1968037519 @default.
- W3089067123 hasRelatedWork W2004818507 @default.
- W3089067123 hasRelatedWork W2091007248 @default.
- W3089067123 hasRelatedWork W2277576025 @default.
- W3089067123 hasRelatedWork W2561002551 @default.
- W3089067123 hasRelatedWork W2727568273 @default.
- W3089067123 hasRelatedWork W2901487801 @default.
- W3089067123 hasRelatedWork W3004430295 @default.
- W3089067123 hasRelatedWork W3089067123 @default.
- W3089067123 hasVolume "31" @default.
- W3089067123 isParatext "false" @default.
- W3089067123 isRetracted "false" @default.
- W3089067123 magId "3089067123" @default.
- W3089067123 workType "article" @default.